Both incidence and mortality of colorectal cancer (CRC) 
Introduction
Colorectal cancer (CRC) is the third most common cancer and cause of cancer death worldwide (1) (2) (3) . Lately, an alarming CRC incidence increase (75% fold) was reported for Romania (4), one of the few countries worldwide where increases in mortality rates by CRC are still occurring (2,9% per year). Up to 30% of CRCs have evidence of a familial component (5) and about 5% are thought to be due to inherited mutations in known genes (2) , the rest being due to low-penetrance alleles (6) . Hereditary Non-Polyposis Colorectal Cancer (HNPCC) is characterized by early-onset CCR occurring in many members of the same family line, increased frequency of multiplicity for CRC, and is mainly attributable to germline mutations in the mismatch repair (MMR) genes MSH2 (OMIM 609309, 2p21), MLH1 (OMIM 120436, 3p22.2) and MSH6 (OMIM 600678, 2p16.3), and to a lesser extent to PMS2 or EPCAM genes. The more appropriate name of Lynch syndrome (LS) -named after Dr. Henry Lynch (7, 8) -has been proposed (9, 10) because the syndrome also involves predisposition to other sites. MMR genes cause LS with a penetrance of approximately 80% for CRC, 60% for endometrial cancer, and well below 20% for the other cancers (stomach, ovaries, small bowel, hepatobiliary epithelium, urogenital epithelium, and brain) (11) . The overall lifetime risk of CRC for patients with LS is estimated to be 80% (12) , while only 5.5% in the general population (13) .
MSH2 mutations are responsible for about 35% of LS families, while MLH1 and MSH6 contribute to 25 and 15% respectively (11) . Mutations in MLH1 and MSH2 are located in all regions of these genes, without obvious hot spots (14) . Mutation-detection strategies must therefore cover the entirety of these genes. The identification of a germline mutation is the gold standard for the diagnosis of Lynch syndrome (15) and is performed by complete Sanger sequencing of MSH2, MLH1, and MSH6 genes (16) , exons and exon-intron boundaries. This is a huge work to do, as the genes are very large (MLH1-19 exons on 100 kb genomic DNA, MSH2-16 exons on 73 kb, MSH6-10 exons on 24 kb) (17) . Patients with LS are included in molecular testing according to inclusion criteria such as Amsterdam I and II (18) , or Bethesda (19) . However, MMR mutations are detected in only 60% of Amsterdam criteria fulfilling families, while up to 20% of families not fulfilling these criteria carry deleterious mutations and are therefore excluded from genetic counselling (20) .
The main problems associated with molecular oncogenetic diagnosis are raised by elevated costs of human and material resources involved for entire gene sequencing and interpretation, as well as by the long period of time the patients have to wait for the result (21) . This period of time (6-8 months for LS diagnostic) is due on the one hand to the laborious interpretation step of the many sequence variants identified by sequencing (22) , and, on the other hand, to the limited number of samples available for analysis at one time (23) . Also, recurrent MMR mutations, detectable by simple procedures and facilitating diagnostic approaches (24, 25) , have rarely been observed worldwide for MMR genes. While classical Sanger sequencing is performed in 96-well plated and would demand 95 available samples for maximum efficiency, performing the entire sequencing on one only sample is a challenging work, due to the difficulty of co-amplifying a great number of gene regions within the same PCR conditions. Such a system would, once implemented, allows a rapid MMR screening for a limited number of patients (down to 1), with reasonable cost-effectiveness, and especially in a very short period of time. We present the development of our optimized protocol, with its 2 variants adapted to 1 or 2 patients simultaneously.
Patients and methods

Patients
We identified and recruited HNPCC families at Sf. Spiridon University Emergency Hospital and the Oncology Institute of Iaşi, Romania. Family inclusion on Lynch syndrome was based on Amsterdam II criteria (18), i.e. at least 3 CRC or Lynch-related cancers in the same family line affecting at least 2 generations, with at least one case diagnosed before age 40. All patients agreed by written informed consent. Personal and family cancer histories were obtained from patients and participating relatives. This study was approved by the local Ethical Committee, UMF Iasi. After gel electrophoresis evaluation, amplicons were purified by ExoSAP-IT™ (Applied Biosystems), following the manufacturer's instructions. Amplicons ware sequenced both in forward and reverse reactions using the BigDye ® Terminator Cycle Sequencing Kit (Applied Biosystems). Sequencing reaction was performed on a 96-Well GeneAmp ® PCR System 9700 (Applied Biosystems), 94ºC/1 min, 25 cycles of 94ºC/10 sec -52ºC/5sec -60ºC/3min. Sequence products were purified using BigDye XTerminator™ Purification Kit (Applied Biosystems), and migrated by capillary electrophoresis on a Life Technologies 3500 Series Genetic Analyzer (Applied Biosystems). We performed analysis of raw data using Seqman ® (DNA Star TM Inc, Madison, WI, USA) and Variant Reporter™ Software v2.0 (ThermoScientific). Mutations were systematically confirmed on an independent different DNA sample.
Molecular analysis
Data interpretation and analysis
All mutations and sequence variants are described according to the recommendations from the Human Genome Variation Society (HGVS), with first nucleotide of DNA numbering being the A from initiator translated ATG (27). We used reference sequences NM_000251.2 (coding), NG_007110.2 (genomic) and NP_000242.1 (proteic) for MSH2, NM_000179.2 (coding), NG_007111.1 (genomic) and NP_000170.1 (proteic) for MSH6, NM_000249.3 (coding), NG_007109.2 (genomic) and NP_000240.1 (proteic) for MLH1 gene respectively. For bioinformatic prediction of variants, we used Alamut ® (Interactive Software TM ) (28).
Results
Although the whole genomic region covered together by MMR genes represents almost 200 kb DNA, the coding region represents overall 9166 nucleotides to sequence. However, sequencing for diagnosis should equally cover exon/intron boundaries, as well as promoter and other regulating regions situated 5' or 3' outside the exons, as mutations in regulatory regions may be deleterious and affect the overall final protein (22) . We calculated 18000 nucleotides to decrypt for a molecular diagnostic test to be validated for MMR genes in Lynch syndrome. All the regions of interest need to be double-strand sequenced and lectured, while the reading sequences need to be accurate enough to avoid any false positive or false negative ones possibly interfering with the final diagnosis.
We defined amplicons covering the coding regions of each exon, as well as exon/intron boundaries. The final coverage area is represented by 16 exons in MSH2 gene (about 5,7 kb), 10 exons in MSH6 gene (about 6,5 kb), and 19 exons in MLH1 gene (about 5,4 kb). This total of 45 exons does not exactly correspond to the actual number of amplicons. The length of concerned exons varies between 200 and 600 bp, the efficiency of the PCR and subsequent sequencing reactions being optimum between 250 and 400 bp. While the majority of exons can generate amplicons within this range, there still are a few examples that need particular adaptation. Exon 4 of MSH6 is exceptionally large (2543 bp), several contiguous amplification fragments being necessary for the entire coding region to be covered. We calculated a total of 8 contiguous amplicons (named 4-1, 4-2, etc.), ranging between 370-580 bp and representing together over 3,6 kb sequence. Exon 12 of MLH1 (371 bp) is particularly complex to amplify and requires 2 contiguous amplicons measuring together 579 bp. Exons 8, 9 and 10 of MSH6 are particularly close to each other on genomic DNA, which hardens primer definition within the region, and brings the necessity of covering the sequence with 4 different amplicons. Nonetheless, some exons prove to be difficult to amplify or to sequence on both strands, due to repetitive regions causing enzyme slippage. In order to ensure an accurate lecture on the entire exon region, we imagined for those cases at least 2 independent amplicon variants.
Developing a one-plate PCR system for each patient According to the description above, an overall amount of 56 amplicons is needed for covering the entire MMR sequence of interest ( Figure  1C ). As each amplicon has theoretically different PCR amplification conditions, efficiency and limitations, the classical and most efficient system consists of amplifying each region independently, for a given number of available DNA samples, with a maximum efficiency for 95 samples (in this case, an entire plate of 96 wells, including a no template control, would be used for each amplicon - Figure 1A ). Amplifying each exon separately allows using different annealing temperatures, PCR program, and even different amounts of template DNA or primers for each reaction, which is beneficial for PCR and sequencing accuracy, and for overall cost-effectiveness.
Unfortunately, 95 samples are rarely available in molecular oncogenetic diagnosis for common laboratories covering limited regions or populations. Also, the period of time necessary for 95 samples to be available considerably delays the duration of each diagnosis. For those reasons, an intermediate amplification system can be imagined, with two or more exons amplifiable in one same plate ( Figure 1B 
As such, an extreme challenge is represented by the co-amplification of all MMR exons in a single plate when only one DNA sample is available ( Figure 1C ). Of course, such a system would answer the question of duration, but would raise problems linked to efficiency, cost-effectiveness, or even accuracy of the final result. In such a system, all exons are co-amplified in a single PCR reaction, which means the amplification conditions for each amplicon should be similar. We defined PCR primers for the amplification of each region of interest, taking into account the particularity of each amplicon in terms of repetitive or GC-rich regions, but we also tried to design primers with appropriate Tms, in order to ensure a common annealing temperature of 54ºC for each amplicon, as well as the possibility of being amplified in a common 35-step PCR reaction. Obviously, these requirements are almost impossible to meet entirely for all 56 amplicons, but for each amplicon we tried to be close enough to the common reaction conditions. Since the same PCR primers were also used for forward and reverse sequencing, we also took into account the correspondence of each primer to a common sequencing reaction.
After multiple steps of optimization regarding primer sequences and relative concentra- 
S1-M2 e7 S1-M2 e6 S1-M2 e5 S1-M2 e4 S1-M2 e3 S1-M2 e2 S1-M2 e1 1 S1-M2 e16 S1-M2 e15 S1-M2 e14 S1-M2 e13 S1-M2 e12 S1-M2 e11 S1-M2 e10 S1-M2 e9 tions, we obtained an acceptable result presented in figure 2B . A comparison between figures 2A and 2B demonstrates the importance of template DNA quality on the overall amplification efficiency.
In figure 2B one can observe most of the exons being correctly and specifically co-amplified in one reaction, in the presence of a single patient DNA template. We can observe lack of amplification for exon M2-e1 (difficult amplification proven in several different reactions) or for exon M1-e17 (accidental random loss, not reproducible). Also, exons like M6-e1 (special conditions) or M2-e16 (accidental) present additional non-specific bands, while exons M1-e6, M1-e7 or M1-e12 show poor amplification with less intense PCR bands. Some of these disadvantages disappeared because they were compensated for in efficient sequencing reactions, while some others directly influenced the accuracy of the final sequence lectured. After testing at least 10 DNA samples in this system, we concluded to the problems commonly appearing in every reaction. Here are some of our main conclusions:
Me-e1 is a very particular exon and its amplification demands a separate touch-down PCR reaction. However, we observed its possible amplification in our common conditions in 20% of the reactions.
Exons M2-e5, M2-e2, M1-e1, M1-e4, M1-e9 can only be sequenced on one strand (either forward or reverse), due to complex repetitive regions 5' or 3' of the exon Exons M6-e1, M6-e7, M6-e8, M1-e5 are the most common to be missed in efficient amplification. However, each one of them appears correctly amplified in more than 50% of the samples. Using several different amplicon variants for those exons generally overcomes the problem.
Up to 5 exons (<10% of the total) are randomly missed from amplification due to general random pipetting or other laboratory environment errors. The missed exons are different for each sample.
The general efficiency widely varies with the quality and quantity of starting DNA. Extracted DNA to be used should always be double-measured and correctly diluted before being used for PCR reactions.
We can conclude that with our system, only 5-10% of the amplicons should be re-amplified in complement reactions, which is comparable with the amount of complements needed in all laboratory sequencing reactions.
Developing a one-plate PCR system for two patients As one can observe in figure 2A , PCR products from 2 different plates can be simultaneously migrated in the same electrophoresis system. This aspect raised the question whether 2 DNA samples could be entirely co-amplified in the same plate. The system described above uses for a patient 7 out of 12 columns of a PCR plate, while some of the exons need re-amplification due to PCR loss. Also, some of the exons are amplified in several variants, which may become obsolete (e.g. M1-e12 can easily be covered by the first amplicon variant). Therefore, we decided to keep the amplicons "working" together in the same plate, while excluding difficult or iterative amplicons from the plate, which can be amplified separately. The novel system we managed to develop is presented in Figure 3A , while the electrophoretic profile from the whole plate (2 patients) can be seen in Figure 3B .
Practically, we pulled out from the plate 8 out of 56 amplicons, and covered 6 columns with the remaining amplicons from Sample 1, the rest of the plate being filled by corresponding amplicons from Sample 2. The eliminated amplicons were M1-e1, M6-e1, M6-e7, M6-e8, M1-e5, M1-e11, M1-e12 (variant 2). These amplicons can be amplified together in a separate system or even in separate reactions each ( Figure 1A and
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Figure 3A (up). Co-amplification of the most efficient 48 exons for 2 patients in the same PCR plate (S=sample, E=amplified exon). Figure 3B (down) . Co-amplification of the most efficient 48 exons for 2 patients in the same PCR plate 1B), depending on the number of available samples. However, one should notice that the main plate we imagined covered more than 85% of the entire region of interest, and the probability of finding deleterious mutations in MMR genes is accordingly inside this plate. In a diagnostic system, when identifying a deleterious pathogenic mutation, one has not to consider continuing the sequence of the other exons. The accuracy of our implemented system can be easily observed in figure 4 . We chose a distant intronic variant upstream exon 8 of MSH2 (c.1277-118G>A), detectable either in homozygous or heterozygous state, both on forward and reverse strands.
Discussion
Improving molecular diagnosis for Lynch syndrome in Romania is essential. Both incidence and mortality are increasing in our country, so early diagnosis and prevention should become national health priorities. The observed epidemiologic trends are similar with those recorded in Western Europe in the early 90s, where the increase awareness about CRC and methods of screening and early diagnosis determined a stabilization of incidence and mortality due to CRC in the late 90s (29) . This moment also corresponds to the emergence and development of Oncogenetics as the medical and diagnostic follow-up of patients and their families presenting a hereditary monogenic risk to cancer. The prognosis for patients with CRC heavily depends on the stage on diagnosis (6): 5-year survival is over 90% for early stages, but only 5% for late ones, which emphasizes early diagnosis. Although overall diagnosis in LS includes germ-line and somatic analysis, the oncogenetic approach is mainly based on germ-line mutation detection by entire MMR gene sequencing. While promising progress has been recently reported by next-generation sequencing, the gold standard in oncogenetic molecular diagnosi remains Sanger sequencing (30) . As shown earlier, this methodology is not only expensive and complex, but also time consuming, therefore a patient should wait a minimum of 8 months for a diagnosis, a period which increases with the limited number of available samples. The challenge we took in this context is to entirely sequence the MMR genes, for a single patient, on a single PCR plate, without losing any of the accuracy of the general sequencing procedure.
We developed an integrated system able to rapidly cover the entire coding region of MSH2, MSH6 and MLH1 by Sanger sequencing. This can be performed for absolutely all 56 needed amplicons in a single PCR amplification plate, followed by separate forward and reverse corresponding sequencing plates. Alternatively, this can be performed for 2 DNA samples simultaneously, in the same plate, for a total of 48/56 amplicons, the remaining ones being amplified separately. In both systems presented, the overall efficiency achieves 95% (maximum we observed -i.e. the number of amplicons not needing re-amplification after the final sequence lecture). However, we have to notice that this efficiency is directly correlated with the quality of template DNA, as well as with the overall accuracy of laboratory workflow. Nonetheless, the systems described are optimized to function on local conditions and equipment, each reproduction in different conditions needing separate optimization.
